Drug price-control advocates, frustrated by the government’s refusal so far to use march-in rights to lower drug prices, are trying a new tack: They are demanding CMS leverage the authority it used to provide free Moderna mRNA COVID-19 vaccine during the pandemic as a tool to now lower the cost of the expensive prostate cancer drug Xtandi. That authority allows the government to gain royalty free rights to a drug and license patents to generic drug makers without requiring evidence...